A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects

[1]  Xiaojiao Li,et al.  Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men , 2021, Expert Opinion on Biological Therapy.

[2]  Borna Payandemehr,et al.  A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects , 2020, Expert opinion on investigational drugs.

[3]  L. Ding,et al.  A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers , 2020, Expert opinion on drug metabolism & toxicology.

[4]  B. Taylor,et al.  First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[5]  Chengxian Guo,et al.  Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers , 2020, British journal of clinical pharmacology.

[6]  Guoping Yang,et al.  Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration. , 2020, Pulmonary pharmacology & therapeutics.

[7]  Bing-he Xu,et al.  Targeted therapeutic options and future perspectives for HER2-positive breast cancer. , 2019, Signal transduction and targeted therapy.

[8]  M. Elwood,et al.  The use of trastuzumab in New Zealand women with breast cancer , 2018, Asia-Pacific journal of clinical oncology.

[9]  A. Secord,et al.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Berger,et al.  Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Zhang,et al.  A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects , 2017, Cancer Chemotherapy and Pharmacology.

[12]  M. Nomoto,et al.  Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial , 2015, BioDrugs.

[13]  E. Winer,et al.  Racial differences in outcomes for patients with metastatic breast cancer by disease subtype , 2015, Breast Cancer Research and Treatment.

[14]  A. Ricart,et al.  A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). , 2014, British journal of clinical pharmacology.

[15]  J. Burggraaf,et al.  A Phase I Dose-Escalation and Bioequivalence Study of a Trastuzumab Biosimilar in Healthy Male Volunteers , 2014, Clinical Drug Investigation.

[16]  J. Baselga,et al.  Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. , 2014, The oncologist.

[17]  Sohita Dhillon,et al.  Trastuzumab Emtansine: First Global Approval , 2013, Drugs.

[18]  P. Klein,et al.  Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer , 2005, Cancer Chemotherapy and Pharmacology.